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Introduction {#sec005}
============

Currently, fibromyalgia syndrome (FMS) is a complex condition affecting patients and can represent a diagnostic challenge for physicians. It is characterized as a pain processing disorder with several distinct secondary symptoms and is associated with low quality of life. \[[@pone.0175370.ref001]--[@pone.0175370.ref004]\] With the multitude of conditions contributing to FMS development, the exact cause of the disorder is unclear. However, it has been hypothesized that FMS is caused by an extensive list of factors, ranging from persistent inflammation and immunologic and muscular abnormalities to triggering \[[@pone.0175370.ref005]\] and maintenance factors. \[[@pone.0175370.ref006]--[@pone.0175370.ref009]\]

Approximately 50% of FMS patients often exhibit other illnesses, such as gastroesophageal reflux disease (GERD), irritable bowel syndrome, and other gastrointestinal disorders. \[[@pone.0175370.ref010]--[@pone.0175370.ref012]\] Among these illnesses, food sensitivities are an essential determinant of inflammation that might be associated to FMS pain. This pain and inflammation can be provoked by particular foods, such as preservatives, eggs, and gluten; however, the food causing FMS symptoms differs from person to person. Until now, few studies have demonstrated which specific foods are connected to FMS pain. \[[@pone.0175370.ref013]--[@pone.0175370.ref015]\] Moreover, recent studies have revealed that the severity of small intestinal bacterial outgrowth (SIBO) is correlated with FMS patients' level of pain, indicating the significance of SIBO in FMS. \[[@pone.0175370.ref016],[@pone.0175370.ref017]\] Furthermore, some researchers believe that FMS and gastrointestinal disorders occur in conjunction because their drivers---inflammation in the brain and gut or bacterial outgrowth in the intestines---are similar. \[[@pone.0175370.ref018]\]

The *Helicobacter pylori* bacterium is typically the causative agent of peptic ulcers, which are sores in the gastric lining, esophagus, or duodenum. These ulcers can also be attributed to the consistent use of nonsteroidal anti-inflammatory drugs (NSAIDs). Various classes of drugs, which often include NSAIDs, are utilized for treating FMS. However, despite their widespread use, results have shown their ineffectiveness in relieving FMS pain. \[[@pone.0175370.ref019]\] Therefore, physicians currently prescribe drugs that affect the central nervous system, \[[@pone.0175370.ref019],[@pone.0175370.ref020]\] targeting the origins of pain reception and slowly eliminating the use of NSAIDs in FMS treatment.

Some physicians believe that stress \[[@pone.0175370.ref021]\] may play a role in the activity of the gut through its effect on hormones and nerves \[[@pone.0175370.ref022],[@pone.0175370.ref023]\], although the link is yet to be confirmed. To the best of our knowledge, the epidemiological evidence for the association of FMS with the risk of PUD is still insufficient. Therefore, in this population-based study, we investigated the relationship between FMS and PUD development.

Methods {#sec006}
=======

Data source {#sec007}
-----------

The National Health Insurance (NHI) program in Taiwan is a single-payer universal insurance program implemented on March 1, 1995, and the NHI program covers approximately 99% of the Taiwanese population. \[[@pone.0175370.ref024]\] The National Health Insurance Administration has authorized the National Health Research Institutes (NHRI) to create an encrypted, secondary database---the National Health Insurance Research Database (NHIRD)---for research purposes. In this study, we analyzed the Longitudinal Health Insurance Database 2000 (LHID2000), which constitutes a subdataset of the NHIRD. The details of the LHID2000 are provided in previous studies. \[[@pone.0175370.ref025],[@pone.0175370.ref026]\] Diagnoses were classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.
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Ethics statement {#sec009}
----------------

The NHIRD encrypts patient personal information to ensure patient privacy, and researchers are provided with anonymous identification numbers associated with the relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR1). The IRB also specifically waived the consent requirement.

Study population {#sec010}
----------------

This study was assessed on the risk of PUD between the individual with and without FMS. FMS, characterized by widespread musculoskeletal pain and multiple tender points, was diagnosed by rheumatologists, neurologists, psychologists, physiatrists, and pain specialists with clinical accuracy, according to the American College of Rheumatology Criteria for the Classification of Fibromyalgia. \[[@pone.0175370.ref027]\] Patients aged ≥20 years who were diagnosed with FMS (ICD-9-CM code 729.1) more than three times within 3 months were included in the FMS cohort. The index date was defined as the first diagnosis date of FMS. To establish a control cohort, patients without FMS were randomly selected and matched to the FMS patients at a 4:1 ratio by age group (every 5-year span), sex, and index date. The exclusion criteria were a history of PUD (ICD-9-CM codes 531--533) before the index date and missing information.

Outcome {#sec011}
-------

The outcome of interest was a new diagnosis of PUD from 2000 to 2011. Both the FMS and control cohorts were monitored until diagnosis of PUD or until the patients were censored because of withdrawal from the NHI program or the end of 2011.

Comorbidities and medications {#sec012}
-----------------------------

To evaluate the potential risk and to control for confounding factors, we included the comorbidities and medications of each patient, namely hyperlipidemia (ICD-9-CM code 272), diabetes (ICD-9-CM code 250), liver cirrhosis (ICD-9-CM codes 571.2, 571.5, and 571.6), alcohol-related illness (ICD-9-CM codes 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, A215, and V11.3), hypertension (ICD-9-CM codes 401--405), depression (ICD-9-CM codes 296.2, 296.3, 300.4, and 311), anxiety (ICD-9-CM code 300.0), sleep disorder (ICD-9-CM codes 307.4 and 780.5), stroke (ICD-9-CM codes 430--438), *H*. *pylori* infection (ICD-9-CM code 041.86), GERD (ICD-9-CM codes 530.11 and 530.81), and proton pump inhibitor (PPI) and NSAID use. Furthermore, we assessed whether FMS medications, including amitriptyline, fluoxetine, duloxetine, milnacipran, meclobemide, tropisetron, pramipexole, and pregabalin, play a role in PUD outcomes.

Statistical analysis {#sec013}
--------------------

The chi-square test was used for analyzing categorical variables, and the Student's *t* test was used for analyzing continuous variables. The cumulative incidence of PUD in the FMS and control cohorts was explored using the Kaplan--Meier method, and the differences were determined using log-rank tests. The incidence density rates were calculated by dividing the number of PUD events by the total follow-up years (per 1st000 person-years). The incidence density rates of PUD for each risk factor and stratified by age, sex, comorbidity, and medications in the both cohorts were calculated. Univariable and multivariable Cox proportional hazard regression models were used to determine the risk factors for PUD, denoted as a hazard ratio (HR) with a 95% confidence interval (CI). Stratified analysis of PUD risk by age, sex, comorbidities and medications was also estimated by the Cox models. The multivariable models included all statistically significant risk factors identified in the univariable model. Data management and analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA). A two-tailed *P* value \< 0.05 was considered significant.

Results {#sec014}
=======

A total of 26068 FMS patients and 104269 controls were included in this study ([Table 1](#pone.0175370.t001){ref-type="table"}). Most patients were aged ≤49 years (53.8%) and were women (54.6%). The mean ages of the FMS and control cohorts were 49.5 ± 16.0 and 49.0 ± 16.3 years, respectively. The comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, stroke, and GERD and NSAID use were more prevalent in the FMS cohort than in the control cohort. The average follow-up durations were 5.59 and 5.87 years in the FMS and control FMS cohorts, respectively. As shown in [Fig 1](#pone.0175370.g001){ref-type="fig"}, the cumulative incidence of PUD was higher in the FMS cohort than in the control cohort (log-rank test *P* \< 0.001).

![Comparison of cumulative incidence of peptic ulcer disease in patients with (dashed line) and those without (solid line) fibromyalgia syndrome.](pone.0175370.g001){#pone.0175370.g001}

10.1371/journal.pone.0175370.t001

###### Demographic characteristics and comorbidities in patients with and without fibromyalgia syndrome.

![](pone.0175370.t001){#pone.0175370.t001g}

                                                  Non-FM cohort   FM cohort     
  ----------------------------------------------- --------------- ------------- ---------
  **Age, year**                                                                 0.99
  ≤ 49                                            56100(53.8)     14025(53.8)   
  50--64                                          28020(26.9)     7005(26.9)    
  65+                                             20149(19.3)     5038(19.3)    
  Mean±SD[^†^](#t001fn002){ref-type="table-fn"}   49.0(16.3)      49.5(16.0)    \<0.001
  **Sex**                                                                       0.99
  Female                                          56972(54.6)     14243(54.6)   
  Male                                            47297(45.4)     11825(45.4)   
  **Comorbidity**                                                               
  Hyperlipidemia                                  14314(13.7)     4900(18.8)    \<0.001
  Diabetes                                        6838(6.56)      2159(8.28)    \<0.001
  Liver cirrhosis                                 468(0.45)       150(0.58)     0.008
  Alcohol-related illness                         2148(2.06)      714(2.74)     \<0.001
  Hypertension                                    24322(23.3)     7673(29.4)    \<0.001
  Depression                                      2561(2.46)      1064(4.08)    \<0.001
  Anxiety                                         3695(3.54)      1624(6.23)    \<0.001
  Sleep disorder                                  12290(11.8)     5072(19.5)    \<0.001
  Stroke                                          2633(2.53)      874(3.35)     \<0.001
  Gastroesophageal reflux disorder                439(0.42)       168(0.64)     \<0.001
  H. pylori infection                             42(0.04)        11(0.04)      0.89
  **Medication**                                                                
  NSAID                                           42400(40.7)     14738(56.5)   \<0.001

Chi-square test;

^†^: *t* test

NSAID, nonsteroidal anti-inflammatory drug

The incidence density rate of PUD was 29.8 per 1000 person-years in the FMS cohort, which was significantly higher than that in the control cohort (19.4 per 1000 person-years; [Table 2](#pone.0175370.t002){ref-type="table"}). The FMS cohort exhibited a 1.40-fold higher risk of PUD compared with the control cohort (95% CI = 1.35--1.45). Compared with patients aged ≤49 years, the risk of PUD was 1.58- and 1.96-fold higher in those aged 50--64 years and ≥65 years (95% CI = 1.52--1.64 and 1.88--2.05, respectively). The risk of PUD was higher in patients with the comorbidities of hyperlipidemia \[adjusted HR (aHR) = 1.22, 95% CI = 1.17--1.27\], liver cirrhosis (aHR = 1.76, 95% CI = 1.48--2.09), hypertension (aHR = 1.24, 95% CI = 1.19--1.29), depression (aHR = 1.19, 95% CI = 1.09--1.29), anxiety (aHR = 1.15, 95% CI = 1.10--1.20), and sleep disorder (aHR = 1.15, 95% CI = 1.10--1.20). The aHR of PUD development was high in patients taking NSAIDs (aHR = 1.28, 95% CI = 1.24--1.33).

10.1371/journal.pone.0175370.t002

###### Incidence and risk factors for peptic ulcer disease.

![](pone.0175370.t002){#pone.0175370.t002g}

  Variable                               Event   PY       Rate[^\#^](#t002fn002){ref-type="table-fn"}   Crude HR (95% CI)                                           Adjusted HR[^†^](#t002fn003){ref-type="table-fn"} (95% CI)
  -------------------------------------- ------- -------- --------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------
  **Fibromyalgia**                                                                                                                                                  
  Non-FM cohort                          11879   612540   19.4                                          1.00                                                        1.00
  FM cohort                              4337    145634   29.8                                          1.53(1.48, 1.58)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.40(1.35, 1.45)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Age, year**                                                                                                                                                     
  ≤ 49                                   6258    435894   14.4                                          1.00                                                        1.00
  50--64                                 5309    198789   26.7                                          1.84(1.77, 1.91)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.58(1.52, 1.64)[\*\*\*](#t002fn004){ref-type="table-fn"}
  65+                                    4649    123491   37.7                                          2.54(2.44, 2.63)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.96(1.88, 2.05)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Sex**                                                                                                                                                           
  Female                                 9287    426012   21.8                                          1.00                                                        1.00
  Male                                   6929    332162   20.9                                          1.06(1.02, 1.09)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.02(0.98, 1.05)
  **Comorbidity**                                                                                                                                                   
  **Hyperlipidemia**                                                                                                                                                
  No                                     12600   659721   19.1                                          1.00                                                        1.00
  Yes                                    3616    98453    36.7                                          1.88(1.81, 1.95)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.22(1.17, 1.27)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Diabetes**                                                                                                                                                      
  No                                     14707   715952   20.5                                          1.00                                                        1.00
  Yes                                    1509    42222    35.7                                          1.68(1.59, 1.77)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.00(0.94, 1.06)
  **Liver cirrhosis**                                                                                                                                               
  No                                     16088   755855   21.3                                          1.00                                                        1.00
  Yes                                    128     2319     55.2                                          2.43(2.04, 2.89)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.76(1.48, 2.09)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Alcohol-related illness**                                                                                                                                       
  No                                     15895   746747   21.3                                          1.00                                                        1.00
  Yes                                    321     11427    28.1                                          1.24(1.11, 1.38)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.06(0.95, 1.19)
  **Hypertension**                                                                                                                                                  
  No                                     10280   592447   17.4                                          1.00                                                        1.00
  Yes                                    5936    165727   35.8                                          2.02(1.96, 2.09)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.24(1.19, 1.29)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Depression**                                                                                                                                                    
  No                                     15610   741182   21.1                                          1.00                                                        1.00
  Yes                                    606     16992    35.7                                          1.63(1.51, 1.77)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.19(1.09, 1.29)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Anxiety**                                                                                                                                                       
  No                                     15325   734729   20.9                                          1.00                                                        1.00
  Yes                                    891     23445    38.0                                          1.73(1.62, 1.85)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.15(1.10, 1.20)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Sleep disorder**                                                                                                                                                
  No                                     13513   676459   20.0                                          1.00                                                        1.00
  Yes                                    2703    81716    33.1                                          1.59(1.52, 1.65)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.15(1.10, 1.20)[\*\*\*](#t002fn004){ref-type="table-fn"}
  **Stroke**                                                                                                                                                        
  No                                     15665   743843   21.1                                          1.00                                                        1.00
  Yes                                    551     14331    38.5                                          1.72(1.58, 1.87)[\*\*\*](#t002fn004){ref-type="table-fn"}   0.97(0.89, 1.06)
  **Gastroesophageal reflux disorder**                                                                                                                              
  No                                     16157   756844   21.4                                          1.00                                                        1.00
  Yes                                    59      1330     44.4                                          1.75(1.35, 2.25)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.16(0.90, 1.51)
  **H. pylori infection**                                                                                                                                           
  No                                     16215   758066   21.4                                          1.00                                                        1.00
  Yes                                    1       108      9.25                                          0.36(0.05, 2.53)                                            \-
  **Medication**                                                                                                                                                    
  **NSAID**                                                                                                                                                         
  No                                     7853    472003   16.6                                          1.00                                                        1.00
  Yes                                    8363    286171   29.2                                          1.69(1.64, 1.74)[\*\*\*](#t002fn004){ref-type="table-fn"}   1.28(1.24, 1.33)[\*\*\*](#t002fn004){ref-type="table-fn"}

PY, person-years;

Rate^\#^, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR^†^: multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, stroke, and gastroesophageal reflux disorder; and NSAID use.

\*\*\**P* \< 0.001

[Table 3](#pone.0175370.t003){ref-type="table"} shows a comparison of PUD incidence and the Cox model-measured hazards ratio between the patients with FMS and those without FMS after stratification by age, sex, comorbidity, and medications. Regardless of stratification, the risk of PUD was higher in the FMS patients than in the controls.

10.1371/journal.pone.0175370.t003

###### Incidence of peptic ulcer disease by age, sex, comorbidity, and medications and Cox model-measured hazard ratio for patients with fibromyalgia syndrome compared those without fibromyalgia syndrome.
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                                                          Non-FM cohort   FM cohort                                                                                            
  ------------------------------------------------------- --------------- ----------- ------ ------ ------- ------ ----------------------------------------------------------- -----------------------------------------------------------
  **Age, years**                                                                                                                                                               
  ≤ 49                                                    4423            351605      12.6   1835   84290   21.8   1.72(1.63, 1.82)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.52(1.44, 1.61)[\*\*\*](#t003fn005){ref-type="table-fn"}
  50--64                                                  3947            161146      24.5   1362   37643   36.2   1.47(1.38, 1.56)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.32(1.24, 1.40)[\*\*\*](#t003fn005){ref-type="table-fn"}
  65+                                                     3509            99789       35.2   1140   23702   48.1   1.36(1.27, 1.45)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.3091.22, 1.39)[\*\*\*](#t003fn005){ref-type="table-fn"}
  **Sex**                                                                                                                                                                      
  Female                                                  6825            344075      19.8   2462   81937   30.1   1.51(1.44, 1.58)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.37(1.31, 1.44)[\*\*\*](#t003fn005){ref-type="table-fn"}
  Male                                                    5054            268465      18.8   1875   63697   29.4   1.56(1.48, 1.64)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.45(1.37, 1.53)[\*\*\*](#t003fn005){ref-type="table-fn"}
  **Comorbidity**[^‡^](#t003fn004){ref-type="table-fn"}                                                                                                                        
  No                                                      5608            408359      13.7   1621   77476   20.9   1.5291.44, 1.61)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.48(1.40, 1.56)[\*\*\*](#t003fn005){ref-type="table-fn"}
  Yes                                                     6271            204181      30.7   2716   68158   39.9   1.30(1.24, 1.36)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.33(1.27, 1.39)[\*\*\*](#t003fn005){ref-type="table-fn"}
  **Medication**                                                                                                                                                               
  **NSAID**                                                                                                                                                                    
  No                                                      6195            402114      15.4   1658   69890   23.7   1.53(1.45, 1.62)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.50(1.42, 1.59)[\*\*\*](#t003fn005){ref-type="table-fn"}
  Yes                                                     5684            210426      27.0   2679   75745   35.4   1.32(1.26, 1.39)[\*\*\*](#t003fn005){ref-type="table-fn"}   1.33(1.27, 1.39)[\*\*\*](#t003fn005){ref-type="table-fn"}

PY, person-years;

Rate^\#^, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR^†^: multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke; and NSAID use.

Comorbidity^‡^: Patients with any one of the comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke.

\*\*\**P* \< 0.001

[Table 4](#pone.0175370.t004){ref-type="table"} displays the results of an analysis of the effects of FMS medications on the risk of PUD compared with the control cohort. FMS patients who did not receive medications exhibited a significantly 1.48-fold higher risk of PUD (95% CI = 1.42--1.53) compared with the controls. Patients receiving meclobemide, fluoxetine, tropisetron, duloxetine, or milnacipran exhibited a significantly 1.64-fold higher risk of PUD (95% CI = 1.28--2.10) compared with the controls. FMS patients who received pregabalin, amitriptyline, or pramipexole exhibited a significantly 1.55-fold higher risk of PUD (95% CI = 1.22--1.97) compared with the controls.

10.1371/journal.pone.0175370.t004

###### Incidence and hazard ratio of peptic ulcer disease among fibromyalgia syndrome patients with and without treatment and compared with controls.

![](pone.0175370.t004){#pone.0175370.t004g}

  Variables                                                                         N        Event   PY       Rate[^\#^](#t004fn002){ref-type="table-fn"}   Crude HR (95% CI)                                           Adjusted HR[^†^](#t004fn003){ref-type="table-fn"} (95% CI)
  --------------------------------------------------------------------------------- -------- ------- -------- --------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------
  **Non- fibromyalgia controls**                                                    104269   11879   612540   19.4                                          1(Reference)                                                1(Reference)
  **Fibromyalgia**                                                                                                                                                                                                      
  Without medications                                                               24201    4118    133790   30.8                                          1.58(1.52, 1.63)[\*\*\*](#t004fn005){ref-type="table-fn"}   1.48(1.42, 1.53)[\*\*\*](#t004fn005){ref-type="table-fn"}
  Treatment with pregabalin, amitriptyline, pramipexole                             265      68      1861     36.5                                          1.95(1.54, 2.48)[\*\*\*](#t004fn005){ref-type="table-fn"}   1.55(1.22, 1.97)[\*\*\*](#t004fn005){ref-type="table-fn"}
  Treatment with meclobemide, fluoxetine, tropisetron, duloxetine, or milnacipran   261      63      1776     35.5                                          1.87(1.46, 2.39)[\*\*](#t004fn004){ref-type="table-fn"}     1.64(1.28, 2.10)[\*\*\*](#t004fn005){ref-type="table-fn"}

PY, person-years;

Rate^\#^, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR^†^: hazard ratio from multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke; and NSAID use.

\*\**P* \< 0.01,

\*\*\**P* \< 0.001

Discussion {#sec015}
==========

This is the first study that showed the long-term risk of PUD in FMS patients by using a population-based database. Through the primary findings, our hypothesis that FMS patients have an elevated risk of PUD is proven true. At the end of the follow-up period, the cumulative frequency of PUD was higher in the FMS cohort than in the control cohort ([Fig 1](#pone.0175370.g001){ref-type="fig"}). The incidence density rates of PUD were 29.8 and 19.4 per 1000 person-years in the FMS and control cohorts, respectively. Moreover, the FMS cohort exhibited a 1.40-fold higher risk of PUD (95% CI = 1.35--1.45) compared with the control cohort ([Table 2](#pone.0175370.t002){ref-type="table"}).

The prevalence rate of comorbidities was also compared between the FMS and control cohorts, as shown in [Table 1](#pone.0175370.t001){ref-type="table"}. Comorbidities such as hyperlipidemia, diabetes, liver cirrhosis, hypertension, depression, anxiety, sleep disorder, stroke, and GERD and PPI and NSAID use were more common in the FMS cohort than in the control cohort. Although not a primary concern of the current study, certain illnesses are expected to be more prevalent in the FMS cohort. \[[@pone.0175370.ref002],[@pone.0175370.ref028]\] Because FMS is a complex condition that is likely multifactorial, both internal and external factors may be triggers for PUD development. \[[@pone.0175370.ref028]--[@pone.0175370.ref032]\]

The mechanisms underlying the association of FMS with an increased risk of PUD are unclear. However, many patients reported an intestinal infection as the initial symptom of FMS; therefore, current and past infection with common intestinal pathogens (i.e., *H*. *pylori*) might induce PUD development in FMS patients. \[[@pone.0175370.ref016],[@pone.0175370.ref017],[@pone.0175370.ref033]\] In addition, gut infection, gut inflammation, medications, stress, and trauma can induce PUD development and damage the mucosal barrier of the gastrointestinal epithelium, \[[@pone.0175370.ref034]--[@pone.0175370.ref036]\] which allows unshielded molecules to enter the bloodstream (known as leaky gut syndrome). The leaky gut causes systemic inflammation and triggers immune responses, leading to a wide array of diseases, including FMS. \[[@pone.0175370.ref034]--[@pone.0175370.ref036]\]

The risk of PUD in FMS patients receiving medications and those not receiving medications was 1.59-fold (95% CI = 1.34--1.89) and 1.48-fold (95% CI = 1.42--1.53) higher than that in the controls. Drugs that affect serotonin levels (fluoxetine, tropisetron, duloxetine, meclobemide, and milnacipran) were shown to increase the risk of gastrointestinal problems by other investigators \[[@pone.0175370.ref037]--[@pone.0175370.ref041]\], but they did not exert more adverse effects than those of other medications (pregabalin, amitriptyline, and pramipexole) in our study (aHR = 1.64 and 1.55, respectively). Our findings show that the listed drugs may not be the cause of ulcers ([Table 4](#pone.0175370.t004){ref-type="table"}).

Increasing evidence has shown that bioenergetics and mitochondrial function are impaired in FMS \[[@pone.0175370.ref042]--[@pone.0175370.ref044]\] and PUD \[[@pone.0175370.ref045]--[@pone.0175370.ref047]\] patients. Although it is unclear whether oxidative stress is a common pathway of PUD and FMS, recent studies have shown that oxidative stress can cause the pathophysiological mechanisms that culminate in the symptoms of PUD and FMS.

This study has some limitations. First, the data extracted from the NHIRD represent only the incidents at discharge; discrepancies between medical treatments and patient diagnoses cannot be directly verified. Second, our study did not assess the severity of FMS and PUD; therefore, we cannot for certain state how the FMS severity affects the subsequent risk of PUD. Moreover, the evidence in this study may be restricted to Taiwan, because it was obtained using the claims data in the NHIRD for feasibility and practicality. Finally, the patients' diet, exposure to smoking and alcohol, and psychological factors are not available in the NHI dataset; therefore, these factors could not be estimated when determining the PUD risk.

Conclusion {#sec016}
==========

In this study, we demonstrated that FMS contributes to an elevated risk of PUD. FMS patients had a high prevalence of comorbidities, and the drugs identified that relieve psychosomatic symptoms in FMS did not increase the likelihood of ulcers. The mechanisms underlying the link between FMS and PUD are still unclear. Additional studies are required to clarify the underlying mechanisms.

Supporting information {#sec017}
======================

###### Checklist of items that should be included in reports of observational studies.

(DOC)

###### 

Click here for additional data file.

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004); China Medical University Hospital; the Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); the NRPB Stroke Clinical Trial Consortium (MOST105-2325-B-039-003); the Tseng-Lien Lin Foundation, Taichung, Taiwan; the Taiwan Brain Disease Foundation, Taipei, Taiwan; the Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

CI

:   confidence interval

FMS

:   fibromyalgia syndrome

GERD

:   gastroesophageal reflux disease

HR

:   hazard ratio

ICD-9-CM

:   International Classification of Diseases, Ninth Revision, Clinical Modification

LHID2000

:   Longitudinal Health Insurance Database 2000

NHIRD

:   National Health Insurance Research Database

NSAIDs

:   nonsteroidal anti-inflammatory drugs

PUD

:   peptic ulcer disease

SIBO

:   small intestinal bacterial outgrowth
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